Jordan Lee, MD
Critical Care Medicine · Honolulu, HINPI 1174847842
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,565 of the $7,421 with a category attached, or 75.0%. 18 manufacturers reported payments, led by Sanofi at 32.6% of the total. 2025 is the largest year on record at $3,163, more than ten times the $167 reported in 2019. Among critical care medicine clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $43.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- Insmed, Inc.$2K
- GSK$862
- AstraZeneca$541
- Boehringer Ingelheim$332
- Regeneron Healthcare Solutions, Inc.$168
- plus $1K from 12 others
What the payments were for
- Consulting fees$1,58121%
- Food & beverage$5,56575%
- Education$2754%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 10 | $2,416 |
| Insmed, Inc. | 62 | $1,931 |
| GSK | 51 | $862 |
| AstraZeneca | 18 | $541 |
| Boehringer Ingelheim | 5 | $332 |
| Regeneron Healthcare Solutions, Inc. | 3 | $168 |
| Sanofi-aventis U.S. LLC | 2 | $164 |
| Mallinckrodt Hospital Products Inc. | 1 | $150 |
| Viatris Specialty LLC | 2 | $147 |
| AbbVie | 5 | $129 |
| Amgen | 1 | $125 |
| Pharming Healthcare, Inc. | 1 | $119 |
| Philips North America LLC | 5 | $108 |
| Mylan Specialty L.p. | 1 | $88 |
| Pfizer | 2 | $72 |
| Verona Pharma, Inc. | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $26 |
| United Therapeutics Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,421 in reported general payments places this provider in the 90th percentile of 31 critical care medicine providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 35 | $384,103 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 334 | $294,333 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 17 | $252,944 |
| NucalaMepolizumab | 12 | $46,741 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $16,300 |
| Advair HfaFluticasone Propion/Salmeterol | 22 | $10,655 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $10,603 |
| Incruse ElliptaUmeclidinium Bromide | 18 | $10,192 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $5,647 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $5,303 |
| BreynaBudesonide/Formoterol Fumarate | 14 | $4,063 |
| Fluticasone-Salmeterol HfaFluticasone Propion/Salmeterol | 11 | $3,819 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,807 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 101 | $2,879 |
| Ventolin HfaAlbuterol Sulfate | 26 | $1,759 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $332 | $384,10335 claims |
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $862 | $378,169409 claims |
| Insmed, Inc.Arikayce | $1,931 | $252,94417 claims |
| AstraZenecaSymbicort | $541 | $3,80711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 31 critical care medicine providers in Hawaii.
Other critical care medicine in Honolulu
- Christian CastanedaHonolulu$34K
- Stephanie GuoHonolulu$9K
- Brent TatsunoHonolulu$5K
- Learned GonzalesHonolulu$4K
- Chad TaoHonolulu$4K
- Benjamin BergHonolulu$3K
- Ronald SchaeferHonolulu$2K
- Nishal BrahmbhattHonolulu$2K
- Ryota SatoHonolulu$2K
- Timothy VosslerHonolulu$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.